January 19, 2018 / 4:43 PM / a year ago

BUZZ-Valeant Pharma: Slide continues on possible threat to diarrhea drug

** Valeant’s U.S.-listed shares down about 4 pct, falling for the fourth session in a row

** Two analysts note concerns about a potential threat to Valeant’s diarrhea drug Xifaxan from Cosmo Pharma’s treatment that is mid-stage trials

** But Cantor Fitzgerald analyst Louise Chen notes Cosmo’s rifamycin expected to file for traveler’s diarrhea, an insignificant percentage of Xiafan’s ~$1 bln in annual sales

** Chen says Xiafan’s revenue is mostly reliant on irritable bowel syndrome associated with diarrhea (IBS-D), reiterates “overweight” rating on VRX

** Wells Fargo’s David Maris says rifamycin could report positive data in IBS-D, and a U.S. approval for TD could be a threat to Xifaxan due to off-label use for IBS-D - Seeking Alpha

** Chen notes widespread off-label use of rifamycin for IBS-D is unlikely as insurers will not reimburse off label usage

** VRX now down a shade over 11 pct in past 4 sessions, cutting its YTD gains to 2 pct (Reporting by Tamara Mathias in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below